Guideline Recommendations for Psoriasis Management

Severity Classification

• Psoriasis severity is defined by the percentage of body surface area (BSA) involved: mild < 3 % BSA, moderate 3–10 % BSA, and severe ≥ 10 % BSA【1】.
• Disease can be considered severe even with lower BSA when high‑impact sites (hands, feet, scalp, face, genital area) are involved or when emotional burden is substantial【1】【2】.

First‑Line Topical Therapy (Limited Disease < 5 % BSA)

• Super‑potent (Class I) topical corticosteroids achieve 58–92 % clinical improvement within 2 weeks【3】.
• Potent (Class II) corticosteroids achieve 68–74 % improvement【1】.
• Adding a vitamin D analogue (e.g., calcipotriene) provides a synergistic effect【4】.

Phototherapy

• Narrow‑band UVB (NB‑UVB) is recommended as second‑line therapy when topical agents fail【5】【2】.
• NB‑UVB is also the safest option during pregnancy for moderate‑to‑severe disease【5】.

Traditional Systemic Therapies

Methotrexate

• Initiate with a test dose of 2.5–5 mg, then increase to a single weekly oral dose up to 30 mg【5】.
• Absolute contraindications: pregnancy, lactation, alcohol abuse, chronic liver disease, immunodeficiency, bone‑marrow hypoplasia【6】.
• Supplement with 1–5 mg folic acid daily (omit on the day of methotrexate)【6】.
• Baseline and periodic monitoring: complete blood count and comprehensive chemistry every 4 weeks; liver function tests every 4 weeks【5】.

Cyclosporine

• Dose 3–5 mg/kg/day for short courses of 3–4 months to achieve rapid disease control【5】.
• Monitor serum creatinine and blood pressure every 2 weeks initially【7】.
• Major precautions: nephrotoxicity, hypertension, increased risk of lymphoma and cutaneous malignancies with prolonged use【7】.

Acitretin

• Non‑immunosuppressive systemic retinoid useful for psoriasis【7】.
• Highly teratogenic; pregnancy must be avoided for 3 years after discontinuation, limiting use in women of child‑bearing potential【7】【5】.

Biologic Therapies (First‑Line for Moderate‑to‑Severe Disease)

• All biologics require baseline laboratory assessment (CBC, metabolic panel, hepatitis serologies, latent TB test) and chest radiography if TB test is positive【1】【7】【9】.
• Absolute contraindication: active severe infection【7】.
• During pregnancy, biologics are classified as Category B (except withdrawn efalizumab, Category C)【7】; infliximab and etanercept have rare reports of VACTERL association【8】.

Monitoring for Biologic Therapy

• Required baseline tests: complete blood count with platelets, comprehensive metabolic panel with liver enzymes, hepatitis panel (HBsAg, anti‑HBs, anti‑HBc, anti‑HCV), latent tuberculosis screening (PPD or QuantiFERON‑Gold), and chest X‑ray if TB screening is positive【1】【7】【9】.

Special Clinical Situations

Erythrodermic Psoriasis

• First‑line: cyclosporine 3–5 mg/kg/day for rapid control【5】.
• Alternatives: infliximab, adalimumab, ustekinumab【8】.
• Initial supportive care: wet compresses with medium‑potency topical steroids and fluid‑balance management【5】.

Palmoplantar Psoriasis

• Despite <5 % BSA, systemic therapy is justified due to disproportionate quality‑of‑life impact【10】.
• First‑line: acitretin (particularly effective)【7】.
• Alternatives: methotrexate, cyclosporine, biologics【7】.
• Targeted phototherapy options: excimer laser 308 nm or bath PUVA【10】.

Pregnancy

• NB‑UVB phototherapy is the safest first‑line option for moderate‑to‑severe disease【5】.
• All biologics are Category B (except efalizumab, withdrawn)【7】.

Combination Therapy

• Methotrexate + UVB (broad or narrow band) or PUVA provides synergistic efficacy【7】.
• Acitretin + NB‑UVB or PUVA reduces cumulative UV dose and helps suppress squamous‑cell carcinoma risk【7】.
• Biologics + topical agents are useful for residual lesions【1】.
• Evidence on safety/efficacy of combining biologics with traditional systemic agents in psoriasis remains limited【8】.

Therapeutic Goals and Follow‑Up

• Minimum target: PASI 75 (75 % improvement).
• Desired target: PASI 90 or absolute PASI < 2.
• Patients should be reassessed periodically for infections, malignancies, and new symptoms【7】【1】.

Baseline Laboratory and Referral Guidelines for Systemic Therapy in Moderate‑to‑Severe Psoriasis

Baseline Laboratory Panel (Applicable to All Systemic Agents)

• A complete blood count with differential and platelets should be obtained before initiating any systemic therapy to identify baseline cytopenias that would contraindicate methotrexate, cyclosporine, or biologic agents (expert consensus). 11, 12, 13
• A comprehensive metabolic panel—including liver enzymes (AST, ALT, alkaline phosphatase, bilirubin) – is required for safe use of methotrexate, cyclosporine, and acitretin (expert consensus). 11, 12, 13
• Serum creatinine and blood urea nitrogen must be measured to assess renal function, which is essential for cyclosporine dosing and for determining methotrexate eligibility (expert consensus). 11, 12, 13

Agent‑Specific Baseline Assessments

Methotrexate

• Women of child‑bearing potential should have a baseline pregnancy test because pregnancy is an absolute contraindication to methotrexate (expert consensus). 11, 12, 13, 14
• No additional laboratory tests beyond the core panel are required prior to starting methotrexate (expert consensus). 14

Cyclosporine

• Baseline blood pressure measurement is mandatory; uncontrolled hypertension precludes cyclosporine use (expert consensus). 11, 12, 13
• Two baseline serum creatinine values obtained at least one week apart are recommended to confirm stable renal function before cyclosporine initiation (expert consensus). 11, 12, 13

Acitretin

• A fasting lipid panel (triglycerides and cholesterol) should be performed before starting acitretin because the drug can exacerbate dyslipidaemia (expert consensus). 11, 12, 13

Rheumatology Referral and Psoriatic Arthritis Screening

• Dermatologists should refer patients who report joint pain, morning stiffness >30 minutes, joint swelling, dactylitis, heel pain, or inflammatory back pain, as 25–30 % of psoriasis patients will develop psoriatic arthritis (clinical prevalence data). 15, 16
• Red‑flag peripheral joint symptoms—swollen or tender joints in the hands, feet, wrists, knees, or ankles—warrant rheumatology evaluation (clinical criteria). 16
• Dactylitis (diffuse swelling of an entire finger or toe) is a specific indicator for referral (clinical criteria). 16
• Enthesitis (pain at tendon or ligament insertion sites, especially the Achilles tendon or plantar fascia) signals possible psoriatic arthritis and should prompt referral (clinical criteria). 16
• Axial manifestations such as inflammatory back pain that improves with activity, worsens with rest, and is accompanied by prolonged morning stiffness are red flags for referral (clinical criteria). 16
• Severe nail changes—including marked pitting, onycholysis, or oil‑drop discoloration—are associated with a higher risk of psoriatic arthritis and should trigger rheumatology assessment (risk marker). 15
• Early rheumatology referral is critical because untreated psoriatic arthritis can cause irreversible joint damage, and dermatologists often under‑diagnose early disease (clinical outcome). 16
• The American College of Rheumatology recommends that all patients with psoriasis be screened for musculoskeletal symptoms at every dermatology visit (guideline recommendation). 16

Considerations for Systemic Therapy Eligibility Beyond BSA

• BSA > 10 % alone does not define severe disease; patients with <10 % BSA involvement of high‑impact areas (e.g., face, genitals, hands, feet) may still require systemic therapy (clinical judgment). 15, 17, 14

All facts are presented in English, with patient‑specific details replaced by generic descriptors.

Psoriasis Management Guidelines (American Academy of Dermatology)

1. Severity Classification & Treatment Selection

• For mild psoriasis (< 3 % body surface area), initiate high‑potency topical corticosteroids combined with vitamin D analogues; for moderate‑to‑severe disease (≥ 3 % BSA) or involvement of high‑impact sites (hands, feet, face, genitals, scalp), start biologic therapy as first‑line treatment. 18
• Disease is classified as severe irrespective of BSA when high‑impact sites are involved or when the emotional burden is substantial. 18

2. Topical Therapy (First‑Line for Mild Disease)

• Calcipotriene provides synergistic benefit when used together with topical corticosteroids. 19
• The fixed‑dose combination of calcipotriene / betamethasone is recommended for moderate‑to‑severe psoriasis. 19
• Coal‑tar preparations are recommended for mild‑to‑moderate psoriasis. 19
• Goeckerman therapy (coal‑tar plus narrowband UVB) is effective in selected patients. 19

3. Phototherapy (Second‑Line When Topicals Fail)

• Narrowband UVB (NB‑UVB) is the preferred phototherapy modality and is more effective than broadband UVB. 20
• NB‑UVB typically requires 20–25 treatments administered 2–3 times per week to achieve significant improvement. 20
• NB‑UVB can be delivered either in‑office or at home, reducing travel burden for patients. 20
• PUVA is highly effective and can produce long‑lasting remissions. [20][21]
• PUVA starting dose should be 70 % of the minimum phototoxic dose, with subsequent doses increased by 40 % if no erythema occurs. 21
• Long‑term PUVA in Caucasian patients increases the risk of squamous‑cell carcinoma and possibly melanoma. 20
• Oral psoralen is contraindicated during pregnancy. [20][21]
• PUVA may cause photo‑aging, lentigines, and occasional nausea. 20
• Combining methotrexate with NB‑UVB or PUVA provides synergistic efficacy. 22

4. Systemic Non‑Biologic Therapy

Methotrexate

• Initiate with a test dose of 2.5–5 mg, then titrate to a single weekly oral dose of up to 25–30 mg; the drug can be given orally or subcutaneously, with subcutaneous administration improving bioavailability. 22
• Supplement with 1–5 mg folic acid daily (omit on methotrexate day) to reduce gastrointestinal and hepatic adverse effects; high‑dose folic acid may diminish methotrexate efficacy. 22
• Absolute contraindications include pregnancy, lactation, desire to conceive within 3 months, cirrhosis or significant hepatic injury, severe cytopenias, and renal impairment. [22][21]20
• Baseline monitoring should include CBC with differential, comprehensive metabolic panel, and a pregnancy test in women of child‑bearing potential; liver function tests are repeated every 3–6 months, with referral to gastroenterology for persistent elevations and annual non‑invasive hepatic serology in at‑risk patients. 22
• Methotrexate is less effective than adalimumab or infliximab for cutaneous psoriasis, but it is efficacious for peripheral psoriatic arthritis (not axial disease) and overall less effective than TNF‑inhibitors for psoriatic arthritis. 22

Cyclosporine

• Recommended dose is 3–5 mg/kg/day for short courses of 3–4 months to achieve rapid disease control; it is best used intermittently rather than as long‑term therapy. [20][21]
• Baseline monitoring requires two serum creatinine measurements (≥ 1 week apart) and blood pressure assessment; serum creatinine and blood pressure are checked every 2 weeks initially. 21
• Major precautions include nephrotoxicity, hypertension, increased risk of lymphoma and cutaneous malignancies with prolonged use, numerous drug interactions, and uncontrolled hypertension as an absolute contraindication. [20][21]

Acitretin

• Acitretin is a non‑immunosuppressive systemic retinoid with a typical response time of about 6 weeks; it is particularly effective for palmoplantar psoriasis. [20][21]
• Baseline labs should include CBC, fasting lipid panel, and liver function tests; periodic monitoring of liver enzymes and serum lipids is required. 21
• The drug is highly teratogenic; pregnancy must be avoided for 3 years after discontinuation, severely limiting its use in women of child‑bearing potential. [20][23]

5. Biologic Therapy (First‑Line for Moderate‑to‑Severe Disease)

• Biologics are recommended as first‑line therapy for moderate‑to‑severe plaque psoriasis because of superior efficacy and acceptable safety profiles. 18
• Baseline laboratory assessment before initiating any biologic should include CBC with differential, comprehensive metabolic panel, hepatitis panel (HBsAg, anti‑HBs, anti‑HBc, anti‑HCV), latent tuberculosis screening (PPD or QuantiFERON‑Gold), and a chest X‑ray if TB screening is positive. 23
• Active serious infection is an absolute contraindication; biologic therapy should be held until the infection resolves. 23

TNF‑α Inhibitors

• Infliximab: 5 mg/kg IV at weeks 0, 2, 6 then every 8 weeks; dose or frequency may be increased (up to 10 mg/kg or every 4 weeks) for better control; especially useful in obese patients due to weight‑based dosing; effective for plaque, palmoplantar, nail, and scalp psoriasis. [18][24]
• Etanercept: 50 mg subcutaneously twice weekly for 12 weeks, then 50 mg weekly for maintenance (some patients may require twice‑weekly maintenance); effective for scalp, nail, pustular, erythrodermic, and inverse psoriasis. 18
• TNF‑α inhibitors increase susceptibility to infections, particularly granulomatous infections (tuberculosis, histoplasmosis, coccidioidomycosis); they may cause paradoxical psoriasis or eczematoid lesions; infliximab and etanercept have rare reports of VACTERL‑type anomalies in pregnancy. [23][24]

IL‑12/23 Inhibitor

• Ustekinumab: 45 mg (< 100 kg) or 90 mg (≥ 100 kg) subcutaneously at weeks 0, 4 then every 12 weeks; effective when TNF‑α inhibitors fail; blocks the p40 subunit of both IL‑12 and IL‑23; well tolerated with no significant laboratory abnormalities; pregnancy category B. 24

• Loss of efficacy over time may occur with all TNF‑α antagonists; management options include increasing dosing frequency, adding combination therapy (e.g., methotrexate, retinoids, phototherapy), or switching to another biologic. 24
• No well‑controlled studies have demonstrated the safety or efficacy of combining biologics with traditional systemic agents in psoriasis. 24

6. Combination Therapy Strategies

• Adding a Class I topical corticosteroid to etanercept for 12 weeks is recommended for moderate‑to‑severe psoriasis. 19
• Adding calcipotriene / betamethasone to adalimumab for 16 weeks accelerates plaque clearance. 19
• All topical corticosteroids may be used concomitantly with any biologic agent. 19
• Adding topical calcipotriene to standard‑dose methotrexate is recommended for moderate‑to‑severe psoriasis. 19

7. Special Clinical Situations

• Erythrodermic psoriasis: First‑line therapy is cyclosporine 3–5 mg/kg/day for rapid disease control; hospital admission is usually required. 21
• Generalized pustular psoriasis: Initial management generally requires hospital admission and systemic agents (e.g., cyclosporine, infliximab). 21
• Psoriatic arthritis: Occurs in 25–30 % of psoriasis patients; TNF‑α inhibitors and IL‑17 inhibitors are approved for treatment; methotrexate is effective for peripheral arthritis but not axial disease. [18][22]
• Pregnancy: NB‑UVB phototherapy is the safest first‑line option for moderate‑to‑severe disease; all biologics are pregnancy category B (except withdrawn efalizumab, category C); methotrexate, acitretin, and oral psoralen are contraindicated. [24][22][20][21]

8. Therapeutic Targets & Monitoring

• Minimum therapeutic target is PASI 75 (75 % improvement). 18
• Recent consensus recommends treating to ≤ 1 % BSA involvement. 19
• Patients on biologics should undergo periodic evaluation for infections and malignancy, receive appropriate vaccinations (avoiding live vaccines), and be counseled that biologic therapy may attenuate vaccine responses. 23

9. Common Pitfalls

• Do not automatically prescribe systemic therapy for limited skin disease when topical agents have failed, as systemic agents carry greater risk. 20
• Do not use commercial sunbeds (UVA) for psoriasis; they are ineffective and may cause premature skin aging and fragility. 21

All facts are derived from American Academy of Dermatology guidelines and cited references.